How to invest in the latest developments in hearing technology
Woman having an ear inspection
Biotech stocks

How to invest in the latest developments in hearing technology

Traditionally dismissed as a relative backwater, this branch of medicine is about to move into the limelight thanks to ageing populations and major br…
19 Feb 2021
Vanquishing the virus: the race to make vaccines for Covid-19
MoneyWeek coronavirus vaccine cover illustration
Biotech stocks

Vanquishing the virus: the race to make vaccines for Covid-19

The extraordinarily rapid development of effective treatments against the coronavirus is a triumph of biotechnology, says Dr Mike Tubbs. He reviews th…
12 Feb 2021
Vexing vaccine delays hit drug firms
Biotech stocks

Vexing vaccine delays hit drug firms

AstraZeneca and Pfizer are being attacked by the EU over what it claims are delays in delivering the Covid vaccine.
28 Jan 2021
AstraZeneca turns the tables as it acquires US pharmaceutical firm Alexion
AstraZeneca CEO Pascal Soriot
Biotech stocks

AstraZeneca turns the tables as it acquires US pharmaceutical firm Alexion

AstraZeneca, the British pharma giant, was almost swallowed up by Pfizer a few years ago. Now it has struck a megadeal of its own. Matthew Partridge r…
17 Dec 2020
The lessons of “Operation Warp Speed” – the race to produce a vaccine
Close up of a syringe
Biotech stocks

The lessons of “Operation Warp Speed” – the race to produce a vaccine

Governments and companies can learn from the extraordinary global effort to create a vaccine to defeat Covid-19, says Matthew Lynn.
13 Dec 2020
Big Pharma deserves its reward for coming up with Covid-19 vaccines
Biotech stocks

Big Pharma deserves its reward for coming up with Covid-19 vaccines

Calls to restrain drug companies' profits from making Covid-19 vaccines are misplaced and would do more harm than good, says Matthew Lynn
29 Nov 2020
More good news as AstraZeneca finds a third Covid vaccine
Biotech stocks

More good news as AstraZeneca finds a third Covid vaccine

Another week, another Covid-19 vaccine. This one from AstraZeneca and Oxford University is homegrown and ready to roll out fast. Matthew Partridge rep…
26 Nov 2020
Cover of MoneyWeek magazine issue no 1022, Friday 23 October 2020

Subscribe to MoneyWeek and get your first six issues FREE

Subscribe to MoneyWeek now and get your first six magazine issues absolutely FREE
Ugur Sahin and Özlem Türeci : the boffins behind the Covid-19 vaccine
People

Ugur Sahin and Özlem Türeci : the boffins behind the Covid-19 vaccine

Ugur Sahin and Özlem Türeci are an unassuming Turkish-German couple who had already made their fortune as biotech entrepreneurs when a strange new vi…
21 Nov 2020
Moderna’s “stunning” second vaccine
Biotech stocks

Moderna’s “stunning” second vaccine

America’s Moderna has come up with a vaccine even more promising than last week’s offering from Pfizer and BioNTech. Matthew Partridge reports
19 Nov 2020
The market reaction to the vaccine shows the value of contrarian thinking
Investment strategy

The market reaction to the vaccine shows the value of contrarian thinking

As the vaccine news has shown, you don't have to think too far outside of the box to get ahead of the herd, says John Stepek.
17 Nov 2020
Is the BioNTech/Pfizer vaccine the big Covid-19 breakthrough?
Biotech stocks

Is the BioNTech/Pfizer vaccine the big Covid-19 breakthrough?

A vaccine that appears so far to be safe and effective is making its way through the final trials before commercialisation. There are reasons to be ch…
12 Nov 2020
Novo Nordisk: Denmark’s dominant drug maker
Share tips

Novo Nordisk: Denmark’s dominant drug maker

Novo Nordisk leads the global market in diabetes treatments and looks a solid long-term buy, says Dr Mike Tubbs.
4 Nov 2020
How to profit from the development of new auto-immune disease drugs
Biotech stocks

How to profit from the development of new auto-immune disease drugs

Some debilitating conditions are caused by the body’s defence mechanism going awry. Dr Mike Tubbs appraises a key subsector of the pharmaceuticals mar…
29 Oct 2020
Cash injection: join the hunt for a coronavirus vaccine
Biotech stocks

Cash injection: join the hunt for a coronavirus vaccine

Covid-19 has renewed interest in preventing the spread of viruses. But the appeal of this rapidly growing sub-sector of the pharmaceuticals market sho…
29 Oct 2020
The MoneyWeek Podcast: the accelerating revolution in healthcare
Biotech stocks

The MoneyWeek Podcast: the accelerating revolution in healthcare

Merryn talks to Dr Paul Jordan, Anna Macdonald, and Dr Gareth Blades of Amati Global investors about some of their favourite small UK companies - incl…
1 Oct 2020
The race for a coronavirus vaccine heats up
Biotech stocks

The race for a coronavirus vaccine heats up

Biotech shares, led by AstraZeneca, are lifted in the race to come up with a coronavirus vaccine.
28 Aug 2020
Profit from the fast growth of the haircare industry
Share tips

Profit from the fast growth of the haircare industry

Our society has become much more image-conscious, while new consumers worldwide want to look good too. From shampoos to new potential cures for baldne…
6 Aug 2020
Which Covid-19 vaccines look likely to be the best bets?
Biotech stocks

Which Covid-19 vaccines look likely to be the best bets?

The race to produce a treatment to prevent Covid-19 has hundreds of entrants. How should investors approach it? Matthew Partridge reports.
24 Jul 2020
Syncona: a biotech trust that's going for a song
Investment trusts

Syncona: a biotech trust that's going for a song

Syncona is an investment trust that invests in promising, privately-held biotechnology companies. It looks too cheap.
15 Jun 2020
AstraZeneca mulls €240bn mega-merger with Gilead Sciences
Stockmarkets

AstraZeneca mulls €240bn mega-merger with Gilead Sciences

Pharma firm AstraZeneca is considering a merger with US peer Gilead Sciences to create a company with a market value of $240bn.
11 Jun 2020
Compound interest: the eighth wonder of the world
Funds

Compound interest: the eighth wonder of the world

Setting up a pharmaceuticals trust in the mid-1990s taught Max King the power of compounding
26 May 2020
The race to defeat the superbugs has just begun
Biotech stocks

The race to defeat the superbugs has just begun

Drug-resistant bacteria are far more dangerous than Covid-19. So will we soon see major progress in developing new antibiotics? It will be a long slog…
22 May 2020